Merck & Co., Inc. Sees Unusually High Options Volume (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) saw some unusual options trading activity on Wednesday. Stock investors acquired 42,821 call options on the stock. This is an increase of 42% compared to the typical daily volume of 30,188 call options.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Merck & Co., Inc. by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after buying an additional 2,185,853 shares in the last quarter. State Street Corp raised its position in shares of Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after buying an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after acquiring an additional 249,110 shares during the period. Finally, Morgan Stanley boosted its position in shares of Merck & Co., Inc. by 0.8% during the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock worth $4,731,018,000 after acquiring an additional 359,486 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

NYSE:MRK traded up $1.85 during mid-day trading on Wednesday, reaching $128.11. 3,053,698 shares of the company’s stock were exchanged, compared to its average volume of 10,928,491. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $131.74. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The business’s fifty day simple moving average is $120.65 and its two-hundred day simple moving average is $117.29. The firm has a market capitalization of $316.42 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 4.95 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the previous year, the firm posted $2.22 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. BMO Capital Markets raised their price objective on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Guggenheim upped their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Finally, Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $133.94.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.